Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening

Daniel X. Yang, MD1, Danil V. Makarov, MD, MHS2, Cary P. Gross, MD3,4, and James B. Yu, MD, MHS1,4

Abstract
Decreased prostate-specific antigen screening since 2008 has generated much concern, including report of recent increase in metastatic prostate cancer incidence among older men. Although increased metastatic disease was temporally proceeded by decreased screening and decreased localized prostate cancer at diagnosis, it is unclear whether the 2 trends are geographically connected. We therefore used the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database to assess geographic-specific associations between changes in localized (2008-2011) and later changes in metastatic prostate cancer incidence (2012-2015). We examined trends from 200 health-care service areas (HSAs) within SEER 18 registries. While on average for each HSA, localized incidence decreased by 27.4 and metastatic incidence increased by 2.3 per 100,000 men per year, individual HSA-level changes in localized incidence did not correlate with later changes in metastatic disease. Decreased detection of localized disease may not fully explain the recent increase in metastatic disease at diagnosis.

Keywords
prostate cancer, cancer screening, epidemiology, PSA, early diagnosis, lead time

Received September 5, 2019. Received revised December 4, 2019. Accepted for publication December 30, 2019.

Introduction
There is conflicting evidence and ongoing controversy regarding the effectiveness of prostate-specific antigen (PSA) screening for prostate cancer.1,2 Analyses of national health survey and claims data suggest PSA screening utilization has decreased since 2008.3,4 Nationally, this decrease in screening has been temporally associated with a decrease in detection of localized prostate cancer, and more recently, an increase in incidence of metastatic prostate cancer among older men.5 However, PSA screening patterns vary by geographic region, and while decreased detection of localized disease has hypothesized to increase likelihood of metastatic disease at diagnosis, it remains unknown if the 2 trends are correlated geographically.6 In other words, one might expect that geographic regions with larger decreases in detection of localized prostate cancer would also have a relatively greater increase in metastatic prostate cancer incidence. Therefore, we used recent population-level registry data to examine geographic-level associations between changes in localized and changes in metastatic prostate cancer at diagnosis.

1 Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA
2 Department of Urology, New York University School of Medicine, NY, USA
3 Department of Medicine, Yale School of Medicine, New Haven, CT, USA
4 Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center at Yale, New Haven, CT, USA

Corresponding Author:
James B. Yu, Department of Therapeutic Radiology, Yale School of Medicine, HRT 138, 333 Cedar St, New Haven, CT 06520, USA.
Email: james.b.yu@yale.edu
**Materials and Methods**

We chose a priori to examine most recent years 2012 to 2015 for changes in metastatic disease, and the preceding years, 2008 to 2011, for changes in localized disease. We assumed a 4-year difference in time interval (“lead time”) between the development of metastatic disease and potential detection via screening due to previous analysis of randomized trial data suggesting clinically occult disease can progress to advanced disease in as little as 4 years.\(^7\) We used the Surveillance, Epidemiology, and End Results (SEER) database to obtain prostate cancer incidence among United States men aged 70 years or older. We chose to examine this age-group due to recent epidemiologic evidence suggesting metastatic prostate cancer incidence is increasing among older men, and the most recent United States Preventive Services Task Force (USPSTF) guidelines recommend against screening among men aged 70 years or older.\(^8\) We used SEER Summary Stage to classify localized (local) and metastatic (distant) prostate cancers.\(^9\)

We calculated incidence rates by National Cancer Institute (NCI) modified health service areas (HSAs), which each represents a relatively self-contained region of hospital care. The original HSAs were formulated by the National Center for Health Statistics and comprised of geographic areas containing one or more counties such that most residents of those areas received care from the same hospitals.\(^10\) The HSAs were subsequently modified by NCI such that individual HSAs did not extend across state boundaries or SEER registries. This resulted in approximately 950 NCI-modified HSAs containing approximately 3200 counties, with considerable variation in geography and population between HSAs.\(^11\) We used population-weighted linear regression with heteroscedasticity-consistent (Huber-White) standard errors to determine correlation between changes in the incidence of localized versus metastatic disease during the study period.

**Results**

A total of over 66,600 cases of localized and 6400 cases of metastatic prostate cancer among men aged 70 or older from 200 HSAs were included for analysis. From 2008 to 2011, localized incidence decreased from 613.6 to 534.2 per 100,000 men aged 70 or older overall, with an average annual decrease for each HSA of 27.4 per 100,000 men (Figure 1A). From 2012 to 2015, metastatic incidence increased from 54.7 to 62.1 per 100,000 men aged 70 or older overall, and for each HSA on average increased by 2.3 per 100,000 men for each year (Figure 1B). There was considerable variation across HSAs, with standard deviations of 37.3 for localized incidence and 9.5 for metastatic incidence, both per 100,000 men per year. Linear regression between HSA-level changes in localized and metastatic disease revealed a correlation coefficient of \(-0.023\) (standard error = 0.017, \(P = .16\), 95% confidence interval: \(-0.056\) to 0.009), representing lack of a statistically significant relation between decreases in localized disease and later increases in metastatic disease within individual health-care service areas (Figure 2). In sensitivity analysis, there is no statistically significant correlation between changes in localized incidence and later changes in metastatic incidence despite increasing the lead time to 5 years or including younger men aged 50 or older.
**Discussion**

Our study shows that there was no statistically significant correlation within HSAs between changes in localized prostate cancer incidence and subsequent changes in metastatic prostate cancer incidence during the time periods compared. Although previous studies in context of USPSTF recommendations against prostate cancer screening have suggested decreased PSA screening as the most plausible explanation for the recent increase in metastatic prostate cancer incidence, our results show that when incidence trends are examined at a more granular geographic level, the relationship between lower rates of localized prostate cancer and higher rates of metastatic disease is not apparent if the lead time between screening detection and development of metastatic disease is assumed to be 4 years.5,12-15 Reasons for increasing rates of metastatic disease besides a lack of screening should be considered, although there are currently no clearly established temporal trends in underlying risk factors, such as race/ethnicity, socioeconomic status, lifestyle factors, family history, and genetic factors to explain the observed changes in metastatic disease incidence.6,16-18 Additionally, it is possible that with greater assumed lead time and further follow-up, a geographic relationship between lower rates of localized prostate cancer and higher rates of metastatic disease may ultimately be revealed.

Despite 3 large randomized clinical trials evaluating its efficacy, prostate cancer screening remains the subject of ongoing controversy.19,21 Most recent 2018 USPSTF statement on prostate cancer screening now recommends individualized decision-making for men aged 55 to 69 years, and against PSA screening for men aged 70 years and older.8 This will likely continue to affect PSA utilization patterns. Moreover, practice pattern changes in disease treatment and monitoring will also continue to shift the balance of benefits and harms of early detection. For example, increased adoption of active surveillance as a conservative management option for low-risk prostate cancer has been suggested to mitigate the potential harms of overdiagnosis and overtreatment.22-24 Future studies are needed to closely monitor changes in disease incidence and possible underlying causal factors, as well as trends in disease treatment options.

Strengths of our study include large cohort taken from a nationally representative cancer registries database, which provides accurate and contemporary incidence rates. Interpretation of our results is limited by study design and available data. We report an association observed by health service areas, which represent relatively small regions and are more subject to statistical fluctuations. Our study is ecological and therefore cannot prove the presence or absence of any causal relationship. Confounding is a major concern inherent to ecologic study design. We cannot account for individual-level factors such as lifestyle and family history. Population-level covariates such as HSA population density, racial and ethnic composition, median income and education level, among others, can also potentially confound our results. We do not report mortality data, which requires longer follow-up. We also assume a relatively short lead time, which may not be reflective of the natural history of prostate cancer progression, and further longitudinal studies are needed. Given the retrospective design of our study, we chose a priori to examine the described age-group and years. Nevertheless, our findings are robust to sensitivity analysis. Although we observe a temporal relationship at the national level, a geographic HSA level association is not observed despite varying age-group or years of diagnosis.

In summary, our population-level observation suggests that decreased detection of localized disease during an era of decreasing utilization of routine PSA screening may not fully explain the recent increase in metastatic disease incidence among older men in the United States if a lead time of 4 years between screen detected cancer and metastatic disease is assumed. Alternative reasons for increased metastatic disease may be evaluated, along with longer assumed lead time between screening detected cancer and subsequent development of metastatic disease.

**Authors’ Note**

This study used deidentified cancer registry data and does not involve human or animal subjects.

**Acknowledgments**

This work was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting; June 2019; Chicago, IL.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Gross received research grants from Johnson & Johnson, and Pfizer, and funding for travel from Flatiron Inc, outside the submitted work. Dr Yu received personal fees from Augmenix Inc, outside the submitted work.

**ORCID iD**

Daniel X. Yang, MD https://orcid.org/0000-0001-6268-4653
James B. Yu, MD, MHS https://orcid.org/0000-0002-3119-3226

**References**

1. Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.
2. Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikov J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(18):1914-1931.
3. Fedewa SA, Ward EM, Brawley O, Jemal A. Recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States. JAMA Intern Med. 2017;177(7):1040-1042.
4. Kearns JT, Holt SK, Wright JL, Lin DW, Lange PH, Gore JL. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. *Cancer*. 2018;124(13):2733-2739.

5. Hu JC, Nguyen P, Mao J, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. *JAMA Oncology*. 2017;3(5):705-707.

6. Houston KA, King J, Li J, Jemal A. Trends in prostate cancer incidence rates and prevalence of prostate specific antigen screening by socioeconomic status and regions in the United States, 2004 to 2013. *J Urol*. 2018;199(3):676-682.

7. Finne P, Fallah M, Hakama M, et al. Lead-time in the European randomised study of screening for prostate cancer. *Eur J Cancer*. 2010;46(17):3102-3108.

8. US Preventative Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(18):1901-1913.

9. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2017 Sub (2000-2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.

10. Makuc DM, Haglund B, Ingram DD, Kleinman JC, Feldman JJ. Health service areas for the United States. *Vital Health Stat 2*. 1991;(112):1-102.

11. Tatalovich Z, Zhu L, Rolin A, Lewis DR, Harlan LC, Winn DM. Geographic disparities in late stage breast cancer incidence: results from eight states in the United States. *Int J Health Geogr*. 2015;14:31.

12. US Preventative Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2008;149(3):185-191.

13. Moyer VA, US Preventative Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2012;157(2):120-134.

14. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. *JAMA*. 2015;314(19):2054-2061.

15. Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. *JAMA Oncology*. 2016;2(12):1657-1660.

16. Negoita S, Feuer EJ, Mariotto A, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. *Cancer*. 2018;124(13):2801-2814.

17. Lee DJ, Mallin K, Graves AJ, et al. Recent changes in prostate cancer screening practices and epidemiology. *J Urol*. 2017;198(6):1230-1240.

18. Park SY, Haiman CA, Cheng I, et al. Racial/ethnic differences in lifestyle-related factors and prostate cancer risk: the Multiethnic Cohort Study. *Cancer Causes Control*. 2015;26(10):1507-1515.

19. Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP Randomized Clinical Trial. *JAMA*. 2018;319(9):883-895.

20. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet*. 2014;384(9959):2027-2035.

21. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. *J Natl Cancer Inst*. 2012;104(2):125-132.

22. De Carvalho TM, Heijnsdijk EAM, De Koning HJ. Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance. *Cancer*. 2018;124(3):507-513.

23. Mahal BA, Butler S, Franco I, et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015. *JAMA*. 2019;321(7):704-706.

24. Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. *Nat Rev Urol*. 2016;13(4):205-215.